FDA Mission Should Not Include Rx Cost Effectiveness, Rep. Allen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Comparative studies should be "untainted" by industry's influence, the Maine Democrat says. He urges full appropriation of funding to AHRQ under the new Medicare law.